# Diversity within the Incidence, Prevalence, Treatment and Outcomes of Patients with IBD

> **NIH ALLCDC U01** · CROHN'S AND COLITIS FDN OF AMERICA, INC. · 2020 · $714,447

## Abstract

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel
disease (IBD), are chronic diseases with no cure. The highest prevalence of IBD is in northern
Europe and North America. Although the United States is home to people of many different
racial and ethnic backgrounds, the incidence, prevalence, and natural history of IBD within
these racial and ethnic groups has not been well described. Importantly, emerging data
suggests Black patients appear to have a more aggressive disease course than other
populations. Coupled with the frequent socioeconomic disparities that face non-White minorities
in the United States, these patients may be at extremely high risk for poor outcomes of IBD. In
this research, we will: 1) build a registry of patients with incident diagnosis of CD and UC, 2)
estimate the incidence and prevalence of CD and UC at a national level using representative
data that encompasses populations from all segments of the socioeconomic and geographic
distribution of the United States, and 3) determine whether race and IBD practice volume are
associated with patterns of care and key outcomes including use of biologics, steroids,
narcotics, hospitalization and surgery at a national level and within high volume IBD centers.
Within the high volume IBD centers we will also test whether socioeconomic status, frequency
of follow-up visits and trust in the healthcare system may confound associations between race,
treatment patterns and outcomes. The results of this work will provide nationally representative
data on the burden of disease, including among non-White minority populations, overcoming
limitations of prior studies and establishing a basis for ongoing IBD surveillance. In addition, this
work has the potential to identify targets for interventions to reduce disparities and improve
outcomes for high risk patients.

## Key facts

- **NIH application ID:** 9966820
- **Project number:** 5U01DP006369-03
- **Recipient organization:** CROHN'S AND COLITIS FDN OF AMERICA, INC.
- **Principal Investigator:** ANDRES HURTADO-LORENZO
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** ALLCDC
- **Fiscal year:** 2020
- **Award amount:** $714,447
- **Award type:** 5
- **Project period:** 2018-09-30 → 2023-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9966820

## Citation

> US National Institutes of Health, RePORTER application 9966820, Diversity within the Incidence, Prevalence, Treatment and Outcomes of Patients with IBD (5U01DP006369-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9966820. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*